Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus

Summary

The purpose is to assess the response of subjects to etanercept (as compared to placebo) in treating the physical signs of mucosal and cutaneous lichen planus. The investigators also wish to assess the effect of etanercept on disease-related itching, pain, and serious adverse events in patients with lichen planus.

Conditions

• Lichen Planus

Interventions

DRUG

Etanercept

etanercept 50 mg twice weekly for 12 weeks

DRUG

Placebo

Sponsors & Collaborators

• Wright State University

  collaborator OTHER

• Tufts Medical Center

  collaborator OTHER

• University of Louisville

  collaborator OTHER

• Wake Forest University Health Sciences

  collaborator OTHER

• University of Michigan

  collaborator OTHER

• Emory University

  collaborator OTHER

• University Hospitals Cleveland Medical Center

  collaborator OTHER

• Icahn School of Medicine at Mount Sinai

  collaborator OTHER

• Oregon Health and Science University

  collaborator OTHER

• The Cleveland Clinic

  collaborator OTHER

• Fivenson, David, M.D.

  collaborator INDIV

• Stanford University

  lead OTHER

Principal Investigators

• David F Fiorentino, MD, PhD · Stanford University

• David F Fiorentino, MD, PhD · Stanford University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2006-08-31

Primary Completion

2009-11-30

Completion

2009-11-30

Countries

• United States

Study Locations